Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Aphea.Bio harvests more series B capital
ECBF has supplied an extension to Aphea.Bio’s series B round, which already included Gemma Frisius Fund, Qbic, Vives and V-Bio Ventures.
Vizgen visualises $37m series B
Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.
Battery Resourcers charges up with $20m
Orbia Ventures led a round for the battery production technology provider that emerged out of Worcester Polytechnic Institute.
Snorkel AI pipes in $35m
GV returned for a series B round that increased the overall funding for Stanford’s machine learning technology developer to $50m.
Syzygy secures $23m series B
The Engine was among the returning investors for the Rice spinout’s series B round, having previously backed a series A in 2019.
Outpace Bio chases down $30m
Lyell Immunopharma co-led a series A round for the gene therapy developer, which partially exploits UW research.
OnQuality orchestrates $20m series A-plus
Cash Capital has returned for OnQuality Pharmaceuticals’s latest round, having already participated in a $15m series A in 2019.
Morphisec raises more in $31m round
Orange and Deutsche Telekom Capital Partners both chipped in as the Ben-Gurion spinout looks to ramp up hiring.

Other News

Noile-Immune negotiates $21.9m series C
The spinout of Yamaguchi University and National Cancer Centre Japan has raised the cash from investors including Dai-ichi Life and Binex.
Baraja bags $31m series B
OpenSea rides wave to $23m
The Stanford-StartX Fund-backed NFT marketplace operator has now secured more than $27m in funding altogether.
Effect Photonics implements series C
Smile Invest and Innovation Industries Fund have co-led a $37m first tranche for TUe spinout Effect Photonics’ series C round.
Variantyx picks IBM for $20m series C
IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.
Cybrexa chooses series B investors
Cybrexa has secured $25m to progress a cancer treatment based on research at Yale University and University of Rhode Island.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg